Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 119

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 1
Chunk 119
---
 

    Series
    A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding 
     -  
     - 
  
    Common
    stock, par value $0.0001; 125,000,000 shares authorized; 34,294,546 and 33,103,860 issued and outstanding, respectively 
     3,429  
     3,310 
  
    Additional
    paid in capital 
     32,145,983  
     30,190,827 
  
    Accumulated
    deficit 
     (32,091,995) 
     (26,022,129)
  
    Total
    stockholders’ equity 
     57,417  
     4,172,008 
  
    Total
    liabilities and stockholders’ equity 
    $2,576,259  
    $6,202,409 

The
accompanying notes are an integral part of these condensed consolidated financial statements

4

JUPITER
NEUROSCIENCES, INC.

CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

    2025  
    2024  
    2025  
    2024 

    Three
    Months Ended  
    Nine
    months ended 

    September
    30,  
    September
    30,  
    September
    30,  
    September
    30, 

    2025  
    2024  
    2025  
    2024 
  
    Expenses: 

    Research
    and development 
    $816,697  
    $91,911  
    $2,042,890  
    $291,655 
  
    General
    and administrative 
     1,480,356  
     401,636  
     4,057,046  
     1,341,271 
  
    Total
    operating expenses 
     2,297,053  
     493,547  
     6,099,936  
     1,632,926 

    Loss
    from operations 
     (2,297,053) 
     (493,547) 
     (6,099,936)